- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Actavis seeks approval for generic opioid-dependence drug
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- Egalet, Shionogi to develop abuse-deterrent opioids
- Upsher-Smith launches morphine sulfate capsules
NEW YORK — A drug for treating opioid dependence has been launched, the manufacturer said Monday.
Orexo announced the introduction of Zubsolv (buprenorphine; naloxone) sublingual tablets for the maintenance treatment of opioid dependence. The drug is designed for use as part of a broader treatment regimen that combines drug therapy and counseling.
The Food and Drug Administration approved Zubsolv in July of this year. Opioid dependence affects nearly 5 million people in the United States, according to a July 2002 study, and while treatable, 60% of those who have it don't receive treatment.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.